PANOVA-3

Background

Phase III, open-label RCT (PANOVA-3). 571 patients with newly diagnosed, unresectable locally advanced pancreatic adenocarcinoma (LA-PAC), ECOG performance status 0-1. Evaluated tumor-treating fields (TTFields) added to gemcitabine + nab-paclitaxel as first-line therapy.

Interventions and follow up

Arm A: TTFields + gemcitabine 1,000 mg/m² + nab-paclitaxel 125 mg/m² (days 1, 8, 15 of 28-day cycle)
Arm B: Gemcitabine + nab-paclitaxel alone
Primary endpoint: Overall survival
Median follow-up: 16+ months

Results

mOS: 16.2 months (TTFields) vs 14.2 months (control), HR 0.82, 95% CI 0.68–0.99, P=.039
Pain-free survival: 15.2 vs 9.1 months, HR 0.74, 95% CI 0.56–0.97, P=.027
Distant PFS: 13.9 vs 11.5 months, HR 0.74, 95% CI 0.57–0.96, P=.022

Adverse events

Dermatologic: Device-related skin AEs in 76.3% (mostly mild-moderate); grade ≥3 skin AE in 7.7%.
Systemic: No additive systemic toxicity with TTFields beyond chemotherapy alone.

Conclusions

TTFields combined with gemcitabine/nab-paclitaxel significantly improved OS, pain-free survival, and distant PFS in unresectable LA-PAC with no added systemic toxicity, representing a meaningful advance in a disease with limited treatment options.

Key Limitations

Open-label design may introduce bias. No statistically significant improvement in PFS or ORR. TTFields requires adherence to a device wear schedule. Unclear whether benefit extends to metastatic disease, as the study was limited to locally advanced patients.

Clinical Context

PANOVA-3 is the first phase III trial to demonstrate an OS benefit with TTFields in pancreatic cancer. The finding expands multimodal approaches to LA-PAC beyond chemotherapy alone, though device tolerance remains a practical consideration.

References

References: Babiker HM et al, J Clin Oncol 2025 (PANOVA-3)